OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Pharmacological Sciences is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Network pharmacology: curing causal mechanisms instead of treating symptoms	444
Organ-on-a-Chip: A New Paradigm for Drug Development	313
NLRP3 and pyroptosis blockers for treating inflammatory diseases	299
Tryptophan Metabolism as a Pharmacological Target	178
Drug Repurposing for Rare Diseases	145
Metformin and Systemic Metabolism	132
Physiological and pharmacological modulation of BAX	116
Iron metabolism: pathophysiology and pharmacology	114
Metastatic colorectal cancer: mechanisms and emerging therapeutics	114
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics	113
The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA	112
Biased Allosteric Modulators: New Frontiers in GPCR Drug Discovery	111
Machine Learning for Biologics: Opportunities for Protein Engineering, Developability, and Formulation	104
Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2	104
Critical Assessment of G Protein-Biased Agonism at the μ-Opioid Receptor	100
Update and latest advances in antiretroviral therapy	100
Progranulin as a therapeutic target in neurodegenerative diseases	87
Nrf2 for cardiac protection: pharmacological options against oxidative stress	85
Targeting the Immune System for Ischemic Stroke	84
Peptide–drug conjugate-based novel molecular drug delivery system in cancer	84
AKAP Signaling Islands: Venues for Precision Pharmacology	82
Advances and challenges in therapeutic targeting of NRF2	81
Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity	80
Recent breakthroughs and future directions in drugging aquaporins	70
Disrupting 3D printing of medicines with machine learning	70

AI-powered therapeutic target discovery	69
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics	68
CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment	61
Computational and artificial intelligence-based methods for antibody development	60
Decoding pseudouridine: an emerging target for therapeutic development	60
Circulating tumor cells in precision medicine: challenges and opportunities	58
FOXO transcription factors as therapeutic targets in human diseases	55
ER stress in obesity pathogenesis and management	54
Overcoming the challenges of tissue delivery for oligonucleotide therapeutics	52
Affinity Hydrogels for Protein Delivery	52
Carbon Monoxide: from Poison to Clinical Trials	49
Present and future of microglial pharmacology	48
3D cell cultures toward quantitative high-throughput drug screening	48
Structural perspective of class B1 GPCR signaling	46
Biological Cells as Therapeutic Delivery Vehicles	44
High-power screening (HPS) empowered by DNA-encoded libraries	44
RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets	41
Membrane protein production and formulation for drug discovery	40
Mouse models of atherosclerosis in translational research	40
Small Molecule Drug Discovery for Neglected Tropical Snakebite	40
Drug Mimicry: Promiscuous Receptors PXR and AhR, and Microbial Metabolite Interactions in the Intestine	40
CRISPR-based therapeutics: current challenges and future applications	39
Opportunities and challenges for microRNA-targeting therapeutics for epilepsy	39
Cholesterol – the devil you know; ceramide – the devil you don’t	39
Nanodelivery of cGAS-STING activators for tumor immunotherapy	39
Biomolecular condensates: new opportunities for drug discovery and RNA therapeutics	39
Nanocarriers for oral delivery of biologics: small carriers for big payloads	39
Autoantibodies as Endogenous Modulators of GPCR Signaling	38
14-3-3 Proteins: Novel Pharmacological Targets in Neurodegenerative Diseases	38
Nanomedicine: controlling nanoparticle clearance for translational success	38
Compstatins: the dawn of clinical C3-targeted complement inhibition	38
The potential of long noncoding RNA therapies	37
Modulation of T cells by tryptophan metabolites in the kynurenine pathway	37
Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic	37
Drug–Exposome Interactions: The Next Frontier in Precision Medicine	36
Recent advances in targeting autophagy in cancer	36
Pharmacological tools to target NKCC1 in brain disorders	36
Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age	35
Copper homeostasis and cuproptosis in cardiovascular disease therapeutics	35
Liquid–liquid phase separation: a principal organizer of the cell’s biochemical activity architecture	34
Discovery of De Novo Macrocyclic Peptides by Messenger RNA Display	34
Overcoming barriers for intra-articular delivery of disease-modifying osteoarthritis drugs	34
Acid-sensing ion channels as potential therapeutic targets	34
Mitochondrial dynamics proteins as emerging drug targets	33
Can Growth Factors Cure Parkinson’s Disease?	33
Targeting galectin-3 in inflammatory and fibrotic diseases	32
Targeting SARS-CoV-2 papain-like protease in the postvaccine era	32
Toll-like receptor-mediated neuroinflammation: relevance for cognitive dysfunctions	32
Triglycerides in Nonalcoholic Fatty Liver Disease: Guilty Until Proven Innocent	32
Beyond ferrostatin-1: a comprehensive review of ferroptosis inhibitors	32

Developing Insulin Delivery Devices with Glucose Responsiveness	32
Single-Cell Techniques and Deep Learning in Predicting Drug Response	32
Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy	31
Engineered antibody fusion proteins for targeted disease therapy	31
Targeting natural killer cells to enhance vaccine responses	31
Treatment strategies for glucose-6-phosphate dehydrogenase deficiency: past and future perspectives	31
Hypothalamic AMPK as a possible target for energy balance-related diseases	30
Targeted protein degrader development for cancer: advances, challenges, and opportunities	30
Targeting intracellular protein–protein interactions with macrocyclic peptides	30
Developing the Cannabinoid Receptor 2 (CB2) pharmacopoeia: past, present, and future	30
Histone post-translational modifications as potential therapeutic targets for pain management	29
GABAA receptors as targets for treating affective and cognitive symptoms of depression	29
Pharmacogenomics in treatment of depression and psychosis: an update	29
Commemorating insulin's centennial: engineering insulin pharmacology towards physiology	29
Ferroptosis of immune cells in the tumor microenvironment	29
The structure and function of YTHDF epitranscriptomic m6A readers	29
Bridging the academia-to-industry gap: organ-on-a-chip platforms for safety and toxicology assessment	28
Electroceuticals in the Gastrointestinal Tract	28
In vivo functions of p75NTR: challenges and opportunities for an emerging therapeutic target	28
Targeting the Sphingosine-1-Phosphate Axis for Developing Non-narcotic Pain Therapeutics	28
Targeting of Potassium Channels in Cardiac Arrhythmias	27
Targeting KNa1.1 channels in KCNT1-associated epilepsy	27
Pharmacological Targeting of Endoplasmic Reticulum Stress in Pancreatic Beta Cells	26
Fragment-based drug design facilitates selective kinase inhibitor discovery	25
Deep mutational scanning for therapeutic antibody engineering	25
Countermeasures in organophosphorus intoxication: pitfalls and prospects	25
Interesting antifungal drug targets in the central metabolism of Candida albicans	25
Ferrous Iron-Dependent Pharmacology	25
Engineering ACE2 decoy receptors to combat viral escapability	25
Challenges and opportunities associated with rare-variant pharmacogenomics	24
Anticancer opportunities at every stage of chemokine function	24
Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19	23
Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunity	23
Adenosine and inflammation: it's time to (re)solve the problem	23
Advances in Targeting GIRK Channels in Disease	22
Targeting the mitochondrial chaperone TRAP1: strategies and therapeutic perspectives	22
Microfluidic technologies for drug discovery and development: friend or foe?	21
Molecular Therapeutics of Pancreatic Ductal Adenocarcinoma: Targeted Pathways and the Role of Cancer Stem Cells	21
Therapeutic inhibition of ferroptosis in neurodegenerative disease	21
Emerging Therapeutic Applications for Fumarates	21
The current toolbox for APOBEC drug discovery	20
Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules	20
Supramolecular nanomedicines through rational design of self-assembling prodrugs	20
Selective and Effective: Current Progress in Computational Structure-Based Drug Discovery of Targeted Covalent Inhibitors	20
Emerging strategies for beta cell transplantation to treat diabetes	20
BH3 Mimetics in AML Therapy: Death and Beyond?	19
Targeting complement in neurodegeneration: challenges, risks, and strategies	19
Delivering AAV to the Central Nervous and Sensory Systems	19
The Potential of 19F NMR Application in GPCR Biased Drug Discovery	18
Targeting sialylation to treat central nervous system diseases	18
Unifying mechanism behind the onset of acquired epilepsy	18
Pharmacological targeting of the tumor–immune symbiosis in glioblastoma	18
A New Chemical Probe Challenges the Broad Cancer Essentiality of CK2	17
Key metrics to expanding the pipeline of successful antibody–drug conjugates	17
Omaveloxolone (SkyclarysTM) for patients with Friedreich’s ataxia	17
Unintended Effects of GPCR-Targeted Drugs on the Cancer Phenotype	17
Subtyping for pancreatic cancer precision therapy	17
Beyond Deterministic Models in Drug Discovery and Development	17